吲哚-3-乙醇酸 | 3050-37-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 吲哚-3-乙醇酸
• 英文名称: indole-3-glycolic acid
• 英文别名: 2-hydroxy-2-(1H-indol-3-yl)acetic acid
• CAS: 3050-37-1
• 化学式: C₁₀H₉NO₃
• 分子量: 191.186
• InChiKey: DJFPJDMKYOGJGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  73.3
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  吲哚-3-乙醇酸 以 水 为溶剂， 反应 20.0h， 生成
  参考文献：
  名称：

  The formation of 2-hydroxy-4-hydroxymethyl-3-(indol-3-yl)cyclopent-2-enone derivatives from ascorbigens

  摘要：

  A facile preparation is described of 3-(indol-3-yl)-2-hydroxy-4-hydroxymethylcyclopent-2-enone and its N-derivatives in 15-40% yields by the degradation of ascorbigen or its N-derivatives in a warm solution of L-ascorbic acid through a sequential domino reaction. The same cyclopentenone derivatives were obtained in 30-40% yields by the condensation of (N-alkylindol-3-yl)glycolic acids with ascorbic acid. 2,6-Dihydroxy-1-(indol-3-yl)hexa-1,4-diene-3-one and 2-hydroxy-4-hydroxymethyl-5-(indol-3-yl)cyclopent-2-enone were identified as intermediates in this reaction. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0008-6215(00)00310-4
• 作为产物：
  描述：

  吲哚 、 sodium glyoxylate 在 盐酸 作用下， 以 水 为溶剂， 反应 24.0h， 生成 吲哚-3-乙醇酸 、 2-hydroxy-2-indol-1-ylacetic acid 、 、 Di-indol-3-yl-essigsaeure
  参考文献：
  名称：

  1-和3-取代的吲哚在吲哚和乙醛酸钠反应中的形成

  摘要：

  除了预期的 3-吲哚基乙醇酸钠 (3a) 外，吲哚和乙醛酸钠在碱性条件下的反应还生成 1-取代衍生物 (4a)。3a 与未反应的吲哚和 4a 部分缩合，产生相应的 3,3'-二吲哚基甲烷衍生物 5a 和 6a。所有化合物均被分离并鉴定为甲酯。

  DOI：

  10.1246/cl.1981.511

文献信息

• Use of 2-ethoxy-1-(ethoxycarbonyl)-1, 2-dihydroquinoline as a convenient reagent for the selective protection or derivatization of 2-hydroxycar☐ylic acids
  作者：Myung Ho Hyun、Moon Hee Kang、Sang Cheol Han

  DOI：10.1016/s0040-4039(99)00509-2

  日期：1999.4

  EEDQ has been utilized as a convenient reagent for the selective protection of the hydroxy group of 2-hydroxycar☐ylic acids. In the presence of an appropriate amine nucleophile, EEDQ has also been utilized as a reagent for the derivatization of both of the hydroxy and car☐ylic acid group of 2-hydroxycar☐ylic acids.Figure options

  EEDQ已被用作方便的试剂，用于选择性保护2-羟基羧酸的羟基。在适当的胺亲核试剂的存在下，EEDQ也已被用作用于衍生2-羟基car☐水合酸的羟基和car☐水合酸基团的试剂。图选项
• Tyrosine phosphatase inhibitors
  申请人：——

  公开号：US20030144338A1

  公开（公告）日：2003-07-31

  A compound of the formula (I): 1 wherein X 1 and X 2 are the same or different and each is a bond or a spacer having 1 to 20 atom(s) in the main chain; one of R 1 and R 2 is a cycle group having substituent(s) selected from 1) an optionally substituted carboxy-C 1-6 alkoxy group and 2) an optionally substituted carboxy-C 1-6 aliphatic hydrocarbon group, wherein the cycle group optionally has additional substituent(s), and the other is an optionally substituted cycle group or a hydrogen atom; and R 3 , R 4 and R 5 are the same or different and each is a hydrogen atom or a substituent, or R 4 may link together with R 3 or R 5 to form an optionally substituted ring; provided that when R 3 is a hydrogen atom, R 4 is a hydrogen atom and R 5 is methyl, X 2 —R 2 is not 4-cyclohexylphenyl; when R 3 is 4-methoxyphenyl, R 4 is a hydrogen atom and R 5 is methyl, X 2 —R 2 is not 4-methoxyphenyl; and when R 1 or R 2 is a hydrogen atom, the adjacent X 1 or X 2 is not a C 1-7 alkylene; or a salt thereof exhibits a protein tyrosine phosphatase inhibitory action and is useful as a prophylactic or therapeutic agent for diabetes or the like.

  式（I）的化合物： 其中X1和X2相同或不同，每个都是主链中具有1至20个原子的键或间隔物； R1和R2中的一个是具有取代基的环基，所述取代基选自1）可选择地取代的羧基-C1-6烷氧基和2）可选择地取代的羧基-C1-6脂肪烃基，其中所述环基可选择地具有额外的取代基，另一个是可选择地取代的环基或氢原子；以及 R3、R4和R5相同或不同，每个是氢原子或取代基，或R4可以与R3或R5结合形成可选择地取代的环； 但是当R3是氢原子时，R4是氢原子且R5是甲基时，X2—R2不是4-环己基苯基；当R3是4-甲氧基苯基，R4是氢原子且R5是甲基时，X2—R2不是4-甲氧基苯基；当R1或R2是氢原子时，相邻的X1或X2不是C1-7烷基； 或其盐具有蛋白酪氨酸磷酸酶抑制作用，并且可用作糖尿病等疾病的预防或治疗剂。
• [EN] PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRIMIDIN-4 (3H)-ONE UTILISÉS EN TANT QU'ANTAGONISTES DE TRPV4
  申请人：RAQUALIA PHARMA INC

  公开号：WO2021221169A1

  公开（公告）日：2021-11-04

  This invention relates to pyrimidin-4(3H)-one derivatives that act as modulators of the TRPV4 receptor. The present invention also relates to processes for the preparation of novel pyrimidin-4(3H)-one derivatives and to their use in the treatment of a wide range of diseases, syndromes, and disorders, in particular for the treatment of inflammatory, pain, and urological diseases or disorders.

  这项发明涉及作为TRPV4受体调节剂的嘧啶-4(3H)-酮衍生物。本发明还涉及新型嘧啶-4(3H)-酮衍生物的制备方法，以及它们在治疗各种疾病、综合症和紊乱中的应用，特别是用于治疗炎症、疼痛和泌尿系统疾病或紊乱。
• Indole derivatives as ppar modulators
  申请人：Conner Eugene Scott

  公开号：US20060166983A1

  公开（公告）日：2006-07-27

  The present invention is directed to a method of treatment by modulating a peroxisome proliferator activated receptor by employing a compound of Structural Formula (I). The variables in (I) are defined herein. Also included are compounds, methods of making compounds, and pharmaceutical compositions. The compounds of the present invention are believed to be effective in treating and preventing Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases.

  本发明涉及一种通过使用结构式(I)的化合物调节过氧化物酶体增殖物激活受体进行治疗的方法。式(I)中的变量在此定义。还包括化合物、制备化合物的方法和制药组合物。本发明的化合物被认为对治疗和预防X综合症、2型糖尿病、高血糖、高脂血症、肥胖症、凝血障碍、高血压、动脉粥样硬化以及其他与X综合症和心血管疾病有关的疾病有效。
• Fused heterocyclic derivates as ppar modulators
  申请人：Conner Eugene Scott

  公开号：US20060217374A1

  公开（公告）日：2006-09-28

  The present invention is directed to a method of treatment by modulating a peroxisome proliferator activated receptor by employing a compound of Structural Formula (I). The variables in I are defined herein. Also included are compounds, methods of making compounds, and pharmaceutical compositions. The compounds of the present invention are believed to be effective in treating and preventing Syndrome X, Type H diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases.

  本发明涉及一种通过利用结构式（I）的化合物来调节过氧化物酶体增殖物激活受体进行治疗的方法。I中的变量在此定义。还包括化合物、制备化合物的方法和制药组合物。本发明的化合物被认为在治疗和预防综合征X、H型糖尿病、高血糖、高脂血症、肥胖症、凝血障碍、高血压、动脉粥样硬化和其他与综合征X和心血管疾病相关的疾病方面具有疗效。